Vireo Growth (VREOF) reported $269M in revenue for fiscal 2025, +170.4% year on year. That ranks #2542 by revenue among 2853 SEC filers and #258 in Healthcare. It posted a net loss of −$68.1M for the same year. Revenue has grown 40.4% a year on average since 2020 ($49.2M then). The fiscal 2025 balance sheet shows $817M in total assets, $123M in cash and $46.2M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $269M | +170.4% | FY20252025-12-31 |
| Gross profitGrossProfit | $127M | +150.3% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$1.0M | −$14.6M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$68.1M | −$40.1M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $3.7M | +$13.9M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $28.3M | +142.2% | FY20252025-12-31 |
| Total assetsAssets | $817M | +193.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $307M | +453.9% | FY20252025-12-31 |
| CashCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $123M | +33.7% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $46.2M | +69.2% | FY20222022-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $106M | −$20.3M | Open → |
| Q2 20262026-06-30 | $209M | −$100,000 | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Vireo Growth Inc.
- Ticker
- VREOF
- Exchange
- OTC
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001771706
Filings
- 10-QAug 14, 2026Open filing →
- 10-QMay 12, 2026Open filing →
- 10-KMar 17, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| VericelVCEL | $276M | $16.5M |
| HarrowHROW | $272M | −$5.1M |
| Viemed HealthcareVMD | $270M | $15.4M |
| Vireo GrowthVREOF | $269M | −$68.1M |
| Ligand PharmaceuticalsLGND | $268M | $124M |
| Iovance BiotherapeuticsIOVA | $264M | −$391M |
| Jushi HoldingsJUSH | $263M | −$68.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Vireo Growth — Key figures |url=https://companiesranked.com/en/company/vireo-growth |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Vireo Growth — Key figures. CompaniesRanked. https://companiesranked.com/en/company/vireo-growthBibTeX
@misc{companiesranked-en-company-vireo-growth-2026,
author = {{CompaniesRanked}},
title = {{Vireo Growth — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/vireo-growth}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104659-26-029561 · March 17, 2026
{{cite web |title=Vireo Growth — Key figures — 10-K (0001104659-26-029561) |url=https://www.sec.gov/Archives/edgar/data/1771706/000110465926029561/vreof-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-17}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.